

Please type a plus sign (+) inside this box ☐

Attorney Docket P1123R1D1C1

EV 351928438 US: Express Mail Number

March 2, 2004: Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Henry B. Lowman,
Leonard G. Presta
Paula M. Jardieu
John Lowe

Title: **Method for Treating IgE-Mediated Disorders (as amended)**

1. Type of Application

- [] This application is for an original, non-provisional application.
- [] This is a non-provisional application claiming priority to provisional application no. __, filed __, the entire disclosure of which is hereby incorporated by reference.
- [X] This is a [] continuation-in-part [X] continuation of USSN 09/716,028, filed November 17, 2000, now allowed, which is a division of USSN 09/109,207, filed June 30, 1998, now USP 6,172,213, [] divisional application claiming priority to application Serial Number 60/051,554, filed July 2, 1997, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)
(Non-provisional)**

80 pages of specification
2 pages of claims
1 page(s) of abstract
19 sheet(s) of drawings
[X] formal [] informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)
An executed declaration of the inventor(s) [] is enclosed [] will follow.

___ An executed declaration of the inventor(s) ☐ is enclosed ☐ will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

X A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

___ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

___ An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet ☐ will follow.

(for cont./div.)

X The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

X A preliminary amendment is enclosed. (Claims 1-47 are cancelled and Claims 48 - 65 are added by this amendment and have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$770.00
Total Claims	18	- 20 =	0	X \$18.00	\$0.00
Independent Claims	1	- 3 =	0	X \$86.00	\$0.00
— Multiple dependent claim(s), if any				+ \$290.00	\$0.00
Filing Fee Calculation					\$770.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$.
A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this transmittal is enclosed.**

9. Additional Papers Enclosed

- ☒ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
☒ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
☐ A new Power of Attorney or authorization of agent.
☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until
 _____ A copy of the petition for extension of time in the **prior** application is attached.

11. Correspondence Address:

X Address all future communications to:

Genentech, Inc.
Attn: Craig G. Svoboda
1 DNA Way
Legal Dept. MS 49
South San Francisco, CA 94080-4990
Customer No: 09157

Respectfully submitted,
GENENTECH, INC.

Date: March 2, 2004


By:



Craig G. Svoboda
Reg. No. 39,044
Telephone No. (650) 1489

CUSTOMER NO: 09157

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of</p> <p>Lowman et al.</p> <p>Serial No.: not yet assigned</p> <p>Filed: herewith</p> <p>For: Method for Treating IgE-Mediated Disorders (as amended)</p>	<p>Group Art Unit: not yet assigned</p> <p>Examiner: not yet assigned</p> <p>Confirmation No: not yet assigned</p> <p>Customer No: 09157</p> <hr/> <p>CERTIFICATION UNDER 37 CFR 1.10</p> <p><u>EV 351928438 US</u> : Express Mail Number <u>March 2, 2004</u>: Date of Deposit</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop Patent Application, P.O. Box 1450, Alexandria, VA 22313-1450</p> <p> Christine Ricks</p>
---	--

TRANSMITTAL LETTER

Mail Stop Patent Application
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

1. Continuation application
2. Formal Drawings
3. Copy of Combined Declaration/Power of Attorney from P1123R1D1 file
4. Information Disclosure Statement
5. Form PTO-1449
6. Metzger et al. reference
7. WO 94/20533 reference
8. WO 92/17207 reference
9. Letter and Request to Use Computer-Readable Sequence Listing
10. Paper copy of Sequence Listing
11. Preliminary Amendment

P1123R1D1C1

12. Continuation transmittal letter
13. Acknowledgment post card

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: March 2, 2004

By: Craig G. Svoboda

Craig G. Svoboda

Reg. No. 39, 044

Telephone No. (650) 225-1489